ATROVENT ADUL

Ipratropium is a quaternary ammonium derivative of atropine 4 that acts as an anticholinergic agent.

It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.

Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the of ipratropium and albuterol was approved in 1996. 12, 11.

Inhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.

Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.

As a single agent, ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older.

It does not alleviate nasal congestion nor sneezing.

Rhinorrhea refers to recurrent or chronic watery nasal discharge.

This condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burden.

Additionally, ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.

The chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness.

As this includes several conditions, the etiology, symptoms, and treatments are diverse.

Ipratropium has also been studied to be used for the treatment of sialorrhea.

Sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivation.

Ipratropium is a short-acting agent that inhibits the parasympathetic nervous system at the level of the airway which then produces bronchodilatation.

The effect of this agent starts after 1-2 hours and it is known to last only from 4-6 hours.

As part of the effect, ipratropium relaxes the bronchial airways which reverse the narrowing that accounts for wheezy breathing, chest tightness, cough and abnormal gas exchange.

In clinical trials where ipratropium was used in the initial management of status asthmaticus, it was demonstrated a clear benefit in pulmonary function in children and adults.

However, the continuous use of ipratropium after an acute asthmatic attack is not proven to be significantly advantageous 1 nor the prophylactic administration of this agent.

Muscarinic acetylcholine receptor

M3 Antagonist Muscarinic acetylcholine receptor M1 Antagonist Muscarinic acetylcholine receptor M2 Antagonist.

Ipratropium is a topically active but poorly absorbed agent.

The lack of absorption potential in the mucosal surfaces is associated with the presence of a charge in the 5-valent nitrogen.

The molecule itself presents very large topic effectiveness however, it does not produce detectable blood levels nor systemic effects.

Serum levels of ipratropium after oral or inhaled administration are very low, corresponding to only 1-2% of the administered dose.

These low levels peak after 1-2 hours and it presents a low bioavailability of 2%.

Ipratropium has a volume of distributions of 4.6 L/kg and hence, it is known to be highly distributed in the tissues.

Ipratropium is metabolized in the gastrointestinal tract by the activity of the cytochrome P-450 isoenzymes.

From the

Oral administered dose, about 90% of the dose is excreted unchanged.

The absorbed portion is partially metabolized by ester hydrolysis to inactive metabolites, tropic acid and tropane.

Hover over products below to view reaction partners Ipratropium N-isopropylnortropium methobromide N-isopropylnortropine-ester methobromide + Phenylacetic acid N-isopropylnortropium bromide.

About 80-100% of the administered dose of ipratropium is excreted in the urine leaving less than 20% of the dose to be eliminated through the feces.

From the urine eliminated portion, almost all the drug is found unchanged.

However, when ipratropium is Oral administered, due to its low absorption, most of the dose is recovered in the feces with a very minimal amount found in the urine.

Ipratropium presents a short half-life of about 1.6 hours.

The average clearance rate of ipratropium is of 2.3 L/min with a renal clearance of 0.9 L/min.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

The reported

LD50 in mice after oral administration of ipratropium is 1500 mg/kg.

Ipratropium was not shown to present carcinogenesis, teratogenesis not mutagenesis potential and it did not present effects on fertility.

The only effect after high administration of ipratropium was a reduction in the conception rate.